NeoGenomics Q4 Earnings Call Highlights

Core Insights - NeoGenomics reported a total revenue of $727 million for full-year 2025, reflecting a 10% increase compared to 2024, with clinical revenue up 15% and non-clinical revenue down 24% [1][7] - The company achieved adjusted gross profit of $335 million, an increase of 8%, and adjusted EBITDA rose 9% to $43.4 million [1] - For Q4 2025, total revenue was $190 million, up 11% year-over-year, with clinical revenue growing 16% while non-clinical revenue declined over 25% [3][4] Financial Performance - Adjusted gross profit for Q4 increased by $5.8 million, or 7%, with adjusted EBITDA rising 10% to $13.4 million [2] - The company reported positive cash flow from operations of $5 million in 2025, with free cash flow improving by over 35% compared to 2024 [1] - Total test volumes rose 11% in Q4, and average unit price (AUP) increased by 5% [8] Strategic Initiatives - NeoGenomics is shifting focus from low-value, high-volume contracts to higher-value, therapy-guided testing, which is expected to drive AUP expansion [6][9] - The company launched five NGS products in 2023, contributing 22% of clinical revenue in Q4, with NGS revenue growing 23% year-over-year [10][11] - The launch of the PanTracer Pro and the commercial rollout of the MRD test RaDaR ST are key initiatives, although contributions from PanTracer LBx depend on reimbursement timing [5][13] Market Outlook - For 2026, NeoGenomics targets revenue between $793 million and $801 million, with adjusted EBITDA expected to be between $55 million and $57 million [18][20] - The company anticipates a growth cadence of approximately 10% year-over-year in Q1, tapering to 8%-9% in Q2, and slightly above 10% in Q4 [19] - Management expects continued modest erosion in the pharma business in 2026, with a potential return to growth in 2027 [22] Operational Developments - The company is consolidating its laboratory information management systems (LIMS) from eight systems to one, with benefits expected to emerge in 2026 and more pronounced impacts in 2027 and 2028 [21] - NeoGenomics is expanding its sales force, particularly targeting ENT physicians for HPV-negative head and neck cancer, with plans to add over 25 oncology sales specialists by Q3 [16]